Skip to main content
Reimbursement strategy

Cost-effective market access strategy for medical technologies in Europe

A holistic approach to reimbursement strategies trusted by global market leaders and SMEs

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Rapid HTAs of three medical devices released in Tuscany

The HTA body of the Tuscany Regional Healthcare issues three types of documents: full HTA reports, rapid HTA reports, and motivational forms. With regional decree 4588 of March 5, 2024, Tuscany Regional Healthcare published two new assessments and one re-assessment of medical devices in the cardiovascular, neuromodulation, and surgical procedures areas.

The assessed technologies are provided below:

  • Neuromodulation system INTELLIS SureScan MRI by Medtronic for patients with chronic neuropathic pain who, with reasonable certainty, will have to undergo an MRI examination following the implant due to certain conditions;
  • Pulsed field ablation catheter FARAWAVE by FARAPULSE for the treatment of paroxysmal atrial fibrillation (update);
  • Nipple prosthesis FIXNIP NRI by FIXNIP for reconstruction of the nipple-areola complex in patients undergoing mastectomy.

See the regional decree and all assessments in Italian here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.